Menu
Semaglutide, a weekly injectable long-acting GLP-1 receptor agonist (glucagon-like peptide), is tailored to individual patient needs and administered under the supervision of doctors and nurse practitioners which helps.
Research indicates that even a 5-10% reduction in body weight can significantly lower the likelihood of developing diabetes, cardiovascular disease, and chronic kidney disease.
Enhances cholesterol levels, consequently reducing the risk of cardiovascular disease.
Promotes Sustainable Weight Loss and Enhanced Overall Health
Aids in reducing insulin resistance and increasing insulin secretion, thereby lowering the risk of developing diabetes mellitus.
Weight loss contributes to decreased blood pressure for patients dealing with hypertension.
Body Mass Index (BMI) is a numerical value derived from weight and height, providing an indication of body fatness. A normal BMI (18.5 to 24.9) suggests a healthy weight, while values outside this range may indicate underweight, overweight, or obesity. However, BMI does not directly measure body fat percentage or distribution, so consulting a healthcare professional is advisable for a comprehensive evaluation.
Reduced erectile dysfunction and heightened libido
Reduced joint discomfort
Consult your provider
Reduced erectile dysfunction and heightened libido
Reduced joint discomfort
Consult your provider
